In men it has been shown, that breast cancer patients who responded with partial or complete remission to Her2/neu-specific antibody trastuzumab have a higher capacity to mediate ADCC in vitro than patients which failed to respond to antibody therapy (Musolino et al., 2008). The gene discussed is ERBB2; the disease is breast carcinoma.